Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  OTC Bulletin Board  >  Brainstorm Cell Therapeutics Inc    

News SummaryMost relevantAll newsSector news 

Brainstorm Cell Therapeutics Inc : BrainStorm’s Clinical Trial is Fast-Tracked to Phase IIa, Representing a Major Milestone for the Company

share with twitter share with LinkedIn share with facebook
share via e-mail
01/07/2013 | 03:51pm CEST
January 7, 2013

BrainStorm's Clinical Trial is Fast-Tracked to Phase IIa,
Representing a Major Milestone for the Company

NEW YORK & PETACH TIKVAH, Israel-January 7, 2013-- BrainStorm Cell Therapeutics (OTC.QB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that the Israeli Ministry of Health has fast-tracked its current Phase I/II ALS safety trial to a Phase IIa dose-escalating trial, significantly expediting the company's clinical development program and saving valuable time. The trial, which will evaluate the safety and preliminary efficacy of BrainStorm's NurOwn stem cell therapy candidate, will be launched immediately at the Hadassah Medical Center in Jerusalem.

The Ministry of Health approved acceleration to a Phase IIa trial based on evaluation of only 12 of the initial cohort of 24 patients in the company's Phase I/II trial at Hadassah. In the Phase IIa trial, the second group of 12 patients will receive combined intramuscular and intrathecal administration of NurOwn cells in three cohorts, with increasing doses. The study participants, who have already been recruited, will be followed for three to six months after transplantation.

"Acceleration to Phase IIa will save us critical time, enabling us to proceed much more quickly with achieving our goal of developing an effective treatment for ALS," commented Dr. Adrian Harel, BrainStorm's CEO.

Professor Dimitrios Karussis, Principal Investigator of BrainStorm's Phase I/II trial at Hadassah, commented: "Based on the positive results we have seen for the first 12 patients, we are eager to begin the next stage of clinical testing, and are delighted that the Ministry of Health has given us the green light to proceed to Phase IIa."

BrainStorm has been conducting a Phase I/II clinical trial in ALS patients at the Hadassah Medical Center in Jerusalem since June 2011, and plans to launch the Phase IIa study immediately. The company is also planning to expand its clinical development to the United States in 2013, pending FDA approval.  Towards that goal, the Company has entered into a Memorandum of Understanding with the University of Massachusetts Medical School and Massachusetts General Hospital to begin ALS human clinical trials at these institutions.

About BrainStorm Cell Therapeutics, Inc.

BrainStorm Cell Therapeutics Inc. is a biotechnology company engaged in the development of first-of-its-kind adult stem cell therapies derived from autologous bone marrow cells for the treatment of neurodegenerative diseases. The Company holds the rights to develop and commercialize its NurOwn™ technology through an exclusive, worldwide licensing agreement with Ramot, the technology transfer company of Tel Aviv University. For more information, visit the company's website at www.brainstorm-cell.com.

Safe Harbor Statement

Statements in this announcement other than historical data and information constitute "forward-looking statements" and involve risks and uncertainties that could cause BrainStorm Cell Therapeutics Inc.'s actual results to differ materially from those stated or implied by such forward-looking statements. Terms and phrases such as "may", "should", "would", "could", "will", "expect", "likely", "believe", "plan", "estimate", "predict", "potential",  and similar terms and phrases are intended to identify these forward-looking statements.  The potential risks and uncertainties include, without limitation, risks associated with BrainStorm's limited operating history, history of losses; minimal working capital, dependence on its license to Ramot's technology; ability to adequately protect the technology; dependence on key executives and on its scientific consultants; ability to obtain required regulatory approvals; and other factors detailed in BrainStorm's annual report on Form 10-K and quarterly reports on Form 10-Q available at http://www.sec.gov.  These factors should be considered carefully, and readers should not place undue reliance on BrainStorm's forward-looking statements.  The forward-looking statements contained in this press release are based on the beliefs, expectations and opinions of management as of the date of this press release. We do not assume any obligation to update forward-looking statements to reflect actual results or assumptions if circumstances or management's beliefs, expectations or opinions should change, unless otherwise required by law. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements.

distributed by
share with twitter share with LinkedIn share with facebook
share via e-mail
09/17 BRAINSTORM CELL THERAPEUTICS : CEO to Present at Two Investor Conferences in Sep..
08/18 BRAINSTORM CELL THERAPEUTICS : Reports Second Quarter 2016 Financial Results and..
08/16 BRAINSTORM CELL THERAPEUTICS INC : BrainStorm's Valuation Doesn't Reflect Potent..
08/11 BRAINSTORM CELL THERAPEUTICS : Management's Discussion and Analysis of Financial..
08/11 BRAINSTORM CELL THERAPEUTICS INC. : Results of Operations and Financial Conditio..
07/28 BRAINSTORM CELL THERAPEUTICS : Announces Positive Top Line Results from the U.S...
07/18 BRAINSTORM CELL THERAPEUTICS INC. : Regulation FD Disclosure, Other Events, Fina..
06/24 BRAINSTORM CELL THERAPEUTICS INC. : Entry into a Material Definitive Agreement, ..
06/22 BRAINSTORM CELL THERAPEUTICS INC. : Submission of Matters to a Vote of Security ..
05/19 BRAINSTORM CELL THERAPEUTICS : Awarded $1.5 Million Non-Dilutive Grant for 2016 ..
More news
Sector news : Biotechnology & Medical Research - NEC
10/25DJMERCK : Profit Rises on Cancer Drugs, Vaccines
10/21DJU.S. HOT STOCKS : Hot Stocks to Watch
10/20DJALKERMES : Shares Surge
10/20 ACTELION : raises guidance for third time this year on strong PAH sales
10/18 Pfizer to start shipping biosimilar version of J&J's Remicade in November
More sector news : Biotechnology & Medical Research - NEC
Financials ($)
Sales 2016 -
EBIT 2016 -7,10 M
Net income 2016 -7,06 M
Debt 2016 -
Yield 2016 -
P/E ratio 2016 -
P/E ratio 2017
Capi. / Sales 2016 0
Capi. / Sales 2017 0
Capitalization 40,3 M
More Financials
Duration : Period :
Brainstorm Cell Therapeuti Technical Analysis Chart | US10501E1029 | 4-Traders
Full-screen chart
Income Statement Evolution
More Financials
Mean consensus OUTPERFORM
Number of Analysts 1
Average target price 5,00 $
Spread / Average Target 131%
Consensus details
EPS Revisions
More Estimates Revisions
Chaim Lebovits President & Chief Executive Officer
Irit Arbel Chairman
Uri Yablonka Chief Operating Officer & Director
Yoram Bibring Chief Financial Officer & Treasurer
Yael Gothelf Vice President-Scientific & Regulatory Affairs
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
CELLTRION, INC.--.--%10 664
LONZA GROUP AG13.37%9 425
ALKERMES PLC-31.39%8 254
More Results